1. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: A double-blind, randomized, placebo-controlled trial. Bipolar Disord 2006; 8: 485–489.
2.
Albert U, De Cori D, Aguglia A, Barbaro F, Bogetto F, Maina G. Increased uric acid levels in bipolar disorder subjects during different phases of illness. J Affect Disord 2015; 173: 170–175.
3.
Ai Y, Wang H, Liu L, Qi Y, Tang S, Tang J, Chen N. Purine and purinergic receptors in health and disease. MedComm 2023, 4, e359.
4.
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie AA, Peters JA, Veale et.al. 2023. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. Br. J. Pharmacol 2023; 180, S23-S144.
5.
Andrejew R, Oliveira-Giacomelli Á, Ribeiro DE, Glaser T, Arnaud-Sampaio VF, Lameu C et al. The P2X7 receptor: central hub of brain diseases. Front Mol Neurosci 2020; 13: 124.
6.
Bartoli F, Crocamo C, Mazza MG, Clerici M, Carrà G. Uric acid levels in subjects with bipolar disorder: A comparative meta-analysis. J Psychiatr Res 2016; 81: 133–139. (a)
7.
Bartoli F, Crocamo C, Gennaro GM, Castagna G, Trotta G, Clerici M et al. Exploring the association between bipolar disorder and uric acid: A mediation analysis. J Psychosom Res 2016; 84: 56–59. (b)
8.
Bartoli F, Crocamo C, Dakanalis A, Brosio E, Miotto A, Capuzzi E et al. Purinergic system dysfunctions in subjects with bipolar disorder: A comparative cross-sectional study. Compr
9.
Psychiatry 2017;73:1–6. (a)
10.
Bartoli F, Crocamo C, Clerici M, Carrà G. Allopurinol as addon treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2017; 210: 10–15. (b)
11.
Bartoli F, Trotta G, Crocamo C, Malerba MR, Clerici M, Carrà G. Antioxidant uric acid in treated and untreated subjects with major depressive disorder: a meta-analysis and meta-regression. Eur Arch Psychiatry Clin Neurosci 2018; 268: 119–127. (a)
12.
Bartoli F, Crocamo C, Bava M, Castagna G, Di Brita C, Riboldi I et al. Testing the association of serum uric acid levels with behavioral and clinical characteristics in subjects with major affective disorders: A cross-sectional study. Psychiatry Res 2018; 269: 118–123. (b)
13.
Bartoli F, Crocamo C, Trotta G, Bava M, Capuzzi E, Castagna G et al. Testing the role of the antioxidant uric acid as a biomarker of suicidal ideation in subjects with major affective disorders: An exploratory study. Gen Hosp Psychiatry 2018; 51: 128–129. (c)
14.
Bartoli F, Burnstock G, Crocamo C, Carrà G. Purinergic signaling and related biomarkers in depression. Brain Sci 2020; 10: 160.
15.
Bernier LP. Purinergic regulation of inflammasome activation after central nervous system injury. J Gen Physiol 2012; 140: 575.
16.
Burnstock G. An introduction to the roles of purinergic signaling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology 2016; 104: 4–17.
17.
Cade J.F.K. Lithium salts in the treatment of psychotic excitement. Med J Aust, 1949; 36: 349–352.
18.
Chatterjee SS, Ghosal S, Mitra S, Mallik N, Ghosal MK. Serum uric acid levels in first episode mania, effect on clinical presentation and treatment response: Data from a case control study. Asian J Psychiatr 2018; 35: 15–17.
19.
Chen AT, Malmstrom T, Nasrallah HA. Allopurinol augmentation in acute mania: A meta-analysis of placebo-controlled trials. J Affect Disord 2018; 226: 245–250.
20.
Chung KH, Huang CC, Lin HC. Increased risk of gout among patients with bipolar disorder: A nationwide population- based study. Psychiatry Res 2010; 180 (2–3): 147–150.
21.
Garrod AB. Gout and Rheumatic Gout. Walton and Maberly, London 1859.
22.
Gonçalves MCB, Andrejew R, Gubert C. The purinergic system as a target for the development of treatments for bipolar disorder. CNS Drugs 2022; 36: 787–801.
23.
Grosso G, Micek A, Castellano S, Pajak A, Galvano F. Coffee, tea, caffeine and risk of depression: A systematic review and dose-response meta-analysis of observational studies. Mol. Nutr. Food Res. 2016; 60: 223–234.
24.
Gubert C, Jacintho Moritz CE, Vasconcelos-Moreno MP, Quadros Dos Santos BTM, Sartori J, Fijtman A et al. Peripheral adenosine levels in euthymic patients with bipolar disorder. Psychiatry Res 2016; 246: 421–426.
25.
Gubert C, Andrejew R, Jacintho Moritz CE, Dietrich F, Vasconcelos- Moreno MP, Dos Santos BTMQ et al. Bipolar disorder and 1513A>C P2RX7 polymorphism frequency. Neurosci Lett 2019 Feb 16; 694: 143–147.
26.
Gubert C, Andrejew R, Leite CE, Moritz CEJ, Scholl J, Figueiro F et al. P2X7 purinergic receptor is involved in the pathophysiology of mania: a preclinical study. Mol Neurobiol 2020; 57: 1347–1360.
27.
Illes P, Rubini P, Ulrich H, Zhao Y, Tang Y. Regulation of microglial functions by purinergic mechanisms in the healthy and diseased CNS. Cells 2020; 9: 1108.
28.
Illes P, Verkhratsky A, Tang Y. Pathological ATPergic signaling in major depression and bipolar disorder. Front Mol Neurosci 2020; 12: 331.
29.
Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL. Adenosine administration produces an antidepressant- like effect in mice: Evidence for the involvement of A1 and A2A receptors. Neurosci Lett 2004; 355: 21–24.
30.
Lange C. Periodische Depressionzustände und ihre Pathogenesis auf dem Boden der harnsäuren Diathese. Verlag von Leopold Voss, Hamburg und Leipzig, 1886.
31.
Lintunen J, Lähteenvuo M, Tanskanen A, Tiihonen J, Taipale H. Allopurinol, dipyridamole and calcium channel blockers in the treatment of bipolar disorder – A nationwide cohort
32.
study. J Affect Disord 2022; 313: 43–48.
33.
Lovatt D, Xu Q, Liu W Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. PNAS 2020; 109: 62656270.
34.
Lucas M, O’Reilly EJ, Pan A, Mirzaei F, Willett WC, Okereke OI, Ascherio A. Coffee, caffeine, and risk of completed suicide: Results from three prospective cohorts of American adults. World J. Biol. Psychiatry 2014; 15: 377–386.
35.
Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J. Clin. Psychiatry 2008; 69(8): 1237–1245.
36.
Malewska MK, Jasińska A, Rybakowski J. The therapeutic effects of lithium, a concept of purinergic theory in affective disorders. Farmakoterapia w Psychiatrii i Neurologii 2016; 32: 97–109.
37.
Malewska M, Permoda-Osip A, Kasprzak P, Niemiec A, Rybakowski J. A study of uric acid concentration in bipolar disorder and schizophrenia. Farmakoterapia w Psychiatrii i Neurologii 2017; 33: 185–187.
38.
Malewska-Kasprzak MK, Permoda-Osip A, Rybakowski J. Disturbances of purinergic system in affective disorders and schizophrenia. Psychiatr Pol. 2019; 53: 577–587.
39.
Malewska-Kasprzak M, Permoda A, Rybakowski JK. Dysfunction of the purinergic system in bipolar disorder. Neuropsychobiology 2022; 81: 265–270.
40.
Oliveira Rda L, Seibt KJ, Rico EP, Bogo MR, Bonan CD. Inhibitory effect of lithium on nucleotide hydrolysis and acetylcholinesterase activity in zebrafish (Danio rerio) brain. Neurotoxicol Teratol 2011; 33(6): 651–657.
41.
Padilla KM, Quintanar-Setephano A, López-Vallejo F, Berumen LC, Miledi R, García-Alcocer G. Behavioral changes induced through adenosine A2A receptor ligands in a rat depression model induced by olfactory bulbectomy. Brain Behav 2018; 8:e00952.
42.
Park H, Suh BS, Lee K. Relationship between daily coffee intake and suicidal ideation. J. Affect. Disord. 2019; 256: 468–472.
43.
Poleszak E, Szopa A, Bogatko K, Wyska E, Wośko S, Świąder K et al. Antidepressant-like activity of typical antidepressant drugs in the forced swim test and tail suspension test in mice is augmented by DMPX, an adenosine A(2A) receptor antagonist. Neurotox. Res. 2019; 35: 344–352.
44.
Recourt K, van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L et al. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. J Psychopharmacol 2023; 34: 1030–1042. (a)
45.
Recourt K, de Boer P, van der Ark P, Benes H, van Gerven JMA, Ceusters M et al. Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder. Transl Psychiatry 2023; 13: 266. (b)
46.
Salvadore G, Viale CI, Luckenbaugh DA, Zanatto VC, Portela LV, Souza DO et al. Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010; 34(6): 819–821.
47.
Sikka P, Behl T, Chandel P, Sehgal A, Singh S, Makeen HA et al. Scrutinizing the therapeutic promise of purinergic receptors targeting depression. Neurotox Res 2022; 40: 1570–1585.
48.
Szopa A, Bogatko K, Serefko A, Wyska E, Wośko S, Świąder K et al. Agomelatine and tianeptine antidepressant activity in mice behavioral despair tests is enhanced by DMPX, a selective adenosine A2A receptor antagonist, but not DPCPX, a selective adenosine A1 receptor antagonist. Pharmacol Rep 2019; 71: 676–681.
49.
Szopa A, Socała K, Serefko A, Doboszewska U, Wróbel A, Poleszak E et al. Purinergic transmission in depressive disorders. Pharmacol Ther. 2021; 224: 107821.
50.
Voelker R. Add-on drug approved for “off” episodes of Parkinson disease. JAMA 2019; 322: 1246.
51.
Yamada K, Kobayashi M, Shiozaki S, Ohta T, Mori A, Jenner P et al. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology (Berl) 2014; 231: 2839–2849.
52.
Yu Y, Feng L, Li J, Lan X, L. A, X. Lv, Zhang M, Chen L. The alteration of autophagy and apoptosis in the hippocampus of rats with natural aging-dependent cognitive deficits. Behav Brain Res 2017; 334: 155–162.
53.
Zhao YF, Verkhratsky A, Tang Y, Illes P. Astrocytes and major depression: The purinergic avenue. Neuropharmacology 2022; 220: 109252.
